title: [Hungarian experience with non-Hodgkin's lymphoma in childhood].
abstract: Between 1990 and 2004, 230 children with non-Hodgkin's lymphoma (NHL) were treated according to the Berlin-Frankfurt-Münster (BFM) protocols (NHL-BFM-90 and -95) in Hungary. The aim of the present study was to summarize our experience with these protocols, to assess the survival rates and to compare the Hungarian data with the international results. The male-to-female ratio was 2.59:1, the mean age at the time of diagnosis was 10 years and 1 month. Ninety-one children had lymphoblastic/T-NHL (LB/T-NHL), 108 B-NHL and 31 anaplastic large cell lymphoma (ALCL). Twenty-eight patients had relapse after a mean time of 13 months from the time of the initial diagnosis. In the above mentioned period, 16 children underwent autologous stem-cell transplantation. Nine patients with B-NHL got anti-CD20 immunotherapy. The five-year overall survival (OS) of our patients is 77.8%+/-3%, the event-free survival (EFS) is 75.1%+/-3%. The 5-year OS and EFS rates were not statistically different in the three histology groups (OS: 71.6%+/-5%, 82.7%+/-4% and 80.3%+/-7%; EFS: 68.7%+/-5%, 81.1%+/-4% and 73.9%+/-8% in LB/T-NHL, B-NHL and ALCL, respectively). We can conclude that non-Hodgkin's lymphoma has a quite good prognosis among the malignant pediatric diseases. The cure rate is over 75%. The Hungarian results are comparable with other international data. In the last five years the mortality during induction was reduced from 10% to 2% and the OS is about 10% better than it was before. In case of relapse or residual disease, therapeutic results can be improved with stem-cell transplantation with or without immunotherapy.
authors.affiliation: II. sz. Gyermekklinika, Semmelweis Egyetem, Budapest, 1094, Hungary. muller@gyer2.sote.hu
authors.forename: Judit
authors.initials: J
authors.lastname: Müller
authors.forename: Mónika
authors.initials: M
authors.lastname: Csóka
authors.forename: Zsuzsanna
authors.initials: Z
authors.lastname: Jakab
authors.forename: Andrea
authors.initials: A
authors.lastname: Ponyi
authors.forename: Hajna
authors.initials: H
authors.lastname: Erlaky
authors.forename: Gábor
authors.initials: G
authors.lastname: Kovács
mesh_terms: D000293:Adolescent; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000009:adverse effects; D002648:Child; D002675:Child, Preschool; D018572:Disease-Free Survival; D005260:Female; D006801:Humans; D006814:Hungary / Q000453:epidemiology; D007167:Immunotherapy / Q000379:methods; D015994:Incidence; D008228:Lymphoma, Non-Hodgkin / Q000175:diagnosis / Q000453:epidemiology / Q000276:immunology / Q000628:therapy; D008297:Male; D015995:Prevalence; D012008:Recurrence; D012074:Remission Induction; D017678:Sex Distribution; D015996:Survival Rate; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents